oxysterol binding protein like 3Genealiases: ORP-3 · ORP3 · OSBP3
Q-omics provides the consensus-scored OSBPL3 profile across patient tissues and cancer cell-line models. OSBPL3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OSBPL3 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, OSBPL3 RNA expression shows 20,326 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where OSBPL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSBPL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSBPL3 survival associations across molecular data types. OSBPL3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSBPL3 RNA expression–survival associations across cancer types. High OSBPL3 expression shows unfavorable associations in MESO, KIRC, COAD, UVM, PAAD and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OSBPL3 RNA expression.
This table summarizes OSBPL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for OSBPL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSBPL3 shows lower tumor expression in KIRC and higher tumor expression in HNSC, COAD, LUAD, LIHC and STAD. The HNSC box plot shows higher OSBPL3 RNA expression in tumor versus normal tissue (log2 FC = +1.188, t-test p < 0.001).
This table shows molecular features associated with OSBPL3 in patient tissues and cancer cell lines. In patient samples, OSBPL3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, OSBPL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BREAST.
